Citations

Clear

1575 citation(s) found for "Im, Gene".

Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
Rauert‐Wunderlich, Hilka , Mottok, Anja , Rimsza, Lisa M. , Ott, German , Klapper, Wolfram , Unterhalt, Michael, Hartmann, Sylvia , Thorns, Christoph, Rymkiewicz, Grzegorz , Dreyling, Martin , Hoster, Eva , Rosenwald, Andreas , Rimsza, Lisa M , Ott, German , Klapper, Wolfram , Holte, Harald , Scott, David W. , Kluin‐Nelemans, Hanneke C. , Hermine, Olivier , Holte, Harald , Hoster, Eva

Mayo Clinic

British Journal of Haematology | August 10, 2018 | Volume: 184 | Issue: 4 | Pages: 616-624

10.1111/bjh.15519 | PMID 30095158 Get It

SummaryMantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki‐67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression‐based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki‐67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk‐adapted prospective clinical trials in the future.
Sex-specific gene and pathway modeling of inherited glioma risk
Ostrom, Quinn T. , COLEMAN, WARREN, Lathia, Justin D. , Liao, Peter, Wrensch, Margaret , Eckel‐Passow, Jeanette E. , Armstrong, Georgina , Rice, Terri, McCoy, Lucie , Hansen, Helen M. , Bernstein, Jonine L. , Claus, Elizabeth B. , Houlston, Richard S. , Jenkins, Robert B. , Johansen, Christoffer , Lai, Rose , Merrell, Ryan , Sadetzki, Siegal , Schildkraut, Joellen M. , Shete, Sanjay , Andersson, Ulrika , Rajaraman, Preetha , Linet, Martha S. , Wang, Zhaoming , Bracci, Paige M. , Molinaro, Annette M. , Pezmecki, M, Prados, Michael D. , Smirnov, Ivan, Wiemels, Joseph L. , Zheng, Shichun, Visvanathan, Kala , Stevens, Victoria L. , Henriksson, Roger , Feychting, Maria , Ahlbom, Anders , Milne, Graham G Giles Roger, McKean‐Cowdin, Roberta , Stampfer, Meir J. , Ruder, Avima M., Hallmans, Göran , Gaziano, J. Michael , Sesso, Howard D. , Purdue, Mark P. , Peters, Ulrike , Buring, Julie E. , Melin, Beatrice , Bondy, Melissa L. , Barnholtz‐Sloan, Jill S. , Houlston, Richard S , Barnholtz-Sloan, Jill S , Wang, Zhaoming , Visvanathan, Kala , Coleman, Warren, Huang, William Y. C. , Rubin, Joshua B , Berens, Michael E. , Speyer, Gil , Armstrong, Georgina , Wiencke, John K. , Amos, Christopher I. , Il’yasova, Dora , Lachance, Daniel Honore , Olson, Sara H. , Chanock, Stephen Jacob , Yeager, Meredith , Berger, Mitchel S. , Chang, Stephen , Clarke, Jennifer , Molinaro, Annette M. , Perry, Arie , Tihan, Tarık , Walsh, Kyle M. , Freeman, Laura E. Beane , Koutros, Stella , Albanes, Demetrius , Michaud, Dominique S. , Marchand, Loı̈c Le , Carreón, Tania , Zeleniuch‐Jacquotte, Anne , White, Emily , Ostrom, Quinn T

Mayo Clinic

Neuro-Oncology | August 8, 2018 | Volume: 21 | Issue: 1 | Pages: 71-82

10.1093/neuonc/noy135 | PMID 30124908 Get It

The MCL35 gene expression proliferation assay predicts high‐risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Holte, Harald , Beiske, Klaus , Boyle, Merrill, Trøen, Gunhild, Blaker, Yngvild Nuvin, Myklebust, June H. , Kvaløy, Sunniva, Rosenwald, Andreas , Rimsza, Lisa M. , Smeland, Erlend B., Kolstad, Arne , Rimsza, Lisa M , Holte, Harald , KVALOY, STEIN, Lingjærde, Ole Christian , Scott, David W.

Mayo Clinic

British Journal of Haematology | August 7, 2018 | Volume: 183 | Issue: 2 | Pages: 225-234

10.1111/bjh.15518 | PMID 30080252 Get It

SummaryPatients with mantle cell lymphoma (MCL) generally have a dismal prognosis. Intensified induction treatment with rituximab and high dose cytarabine (R_HDAC), and consolidation with high‐dose therapy with autologous stem cell support has resulted in 10‐year overall survival (OS) higher than 60%. However, the clinical course varies. Diagnostic tools capable of stratifying patients include the MCL International Prognostic Index (MIPI), gene expression‐based proliferation signature, Ki‐67 proliferation index or tumour cell morphology. Here, we tested the performance of a newly developed Nanostring‐based RNA expression‐based proliferation assay (MCL35) on formalin‐fixed paraffin‐embedded tumour tissue from younger patients recruited in or treated according to Nordic MCL protocols compared to the prognosticators listed above. Seventy‐four patients were included and the assay performed well in all cases except four, which had inadequate RNA quality. The patients were evenly distributed in the MCL35 low‐, intermediate‐ and high‐risk categories. MCL35 low‐ and intermediate‐ risk groups had overlapping progression‐free survival (PFS), while patients in the high‐risk category had significantly inferior PFS. Combining MCL35 with MIPI or the MIPI‐C (MIPI with the addition of binary Ki67 score +/−30%) showed a better discrimination than either assessment alone. In conclusion, the MCL35 assay alone or combined with MIPI or MIPI‐C scores can identify patients who still have a dismal outcome despite intensified treatment.
M 3 RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction
Singh, Raman Deep , Hillestad, Matthew L. , Livia, Christopher , Alekseev, Alexey E., Witt, Tyra A. , Stalboerger, Paul G., Behfar, Atta , Yamada, Satsuki , Behfar, Atta , Livia, Christopher , Li, Mark, Terzic, André

Mayo Clinic

Tissue Engineering Part A | July 26, 2018 | Volume: 25 | Issue: 1-2 | Pages: 145-158

10.1089/ten.tea.2017.0445 | PMID 30047313 Get It

Editorial: Arthritis Gene Therapy Using Interleukin‐1 Receptor Antagonist
Evans, Christopher H. , Evans, Christopher

Mayo Clinic

Arthritis & Rheumatology | July 23, 2018 | Volume: 70 | Issue: 11 | Pages: 1699-1701

10.1002/art.40675 | PMID 30035385 Get It

Epigenome Editing Enters the Arena. A New Tool to Reveal (and Reverse?) Pathologic Gene Regulation
Tan, Qi , Tschumperlin, Daniel J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 18, 2018 | Volume: 198 | Issue: 5 | Pages: 549-551

10.1164/rccm.201807-1239ed | PMID 30016116 Get It

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases
Gentile, Massimo , Reda, Gianluigi , Mauro, Francesca Romana , Rossi, Davide , Renzo, Nicola Di , Molica, Stefano , Angrilli, F., Chiarenza, Annalisa , Cutrona, Giovanna , Chaffee, Kari G. , D’Arrigo, Graziella , Vigna, Ernesto , Recchia, Anna Grazia , Gaïdano, Gianluca , Raimondo, Francesco Di , Fais, Franco , Foà, Robin , Neri, Antonino , Rabe, Kari G. , Gentile, Massimo , Reda, Gianluigi , Mauro, Francesca R , Molica, Stefano , Chiarenza, Annalisa , Gaidano, Gianluca , Morabito, Fortunato , Shanafelt, Tait D. , Parikh, Sameer A. , Tripepi, Giovanni Luigi , Cortelezzi, Agostino , Ferrarini, Manlio

Mayo Clinic

American Journal of Hematology | July 9, 2018 | Volume: 93 | Issue: 9 | Pages: No page available

10.1002/ajh.25206 | PMID 29984867 Get It

Heat Stress and Thermal Ablation Induce Local Expression of Nerve Growth Factor Inducible (VGF) in Hepatocytes and Hepatocellular Carcinoma: Preclinical and Clinical Studies
Jondal, Danielle E. , Butters, Kim A., Anderson, Jill , Roberts, Lewis R. , Callstrom, Matthew R. , Woodrum, David A. , Knudsen, Bruce E. , Anderson, Jill L, Roberts, Lewis R , Thompson, Scott M.

Mayo Clinic

Gene Expression | July 4, 2018 | Volume: 19 | Issue: 1 | Pages: 37-47

10.3727/105221618x15305531034617 | PMID 29973305 Get It

The purposes of this study were to test the hypothesis that heat stress and hepatic thermal ablation induce nerve growth factor inducible (VGF) and to determine intrahepatic versus systemic VGF expression induced by thermal ablation in vivo and in patients. Hepatocytes and HCC cells were subjected to moderate (45°C) or physiologic (37°C) heat stress for 10 min and assessed for VGF expression at 0‐72 h post-heat stress ( n ≥ 3 experiments). Orthotopic N1S1 HCC-bearing rats were randomized to sham or laser thermal ablation (3 W × 90 s), and liver/serum was harvested at 0‐7 days postablation for analysis of VGF expression ( n ≥ 6 per group). Serum was collected from patients undergoing thermal ablation for HCC ( n = 16) at baseline, 3‐6, and 18‐24 h postablation and analyzed for VGF expression. Data were analyzed using ordinary or repeated-measures one-way analysis of variance and post hoc pairwise comparison with Dunnett’s test. Moderate heat stress induced time-dependent VGF mRNA (3- to 15-fold; p < 0.04) and protein expression and secretion (3.1- to 3.3-fold; p < 0.05). Thermal ablation induced VGF expression at the hepatic ablation margin at 1 and 3 days postablation but not remote from the ablation zone or distant intrahepatic lobe. There was no detectable serum VGF following hepatic thermal ablation in rats and no increase in serum VGF following HCC thermal ablation in patients at 3‐6 and 18‐24 h postablation compared to baseline (0.71- and 0.63-fold; p = 0.27 and p = 0.16, respectively). Moderate heat stress induces expression and secretion of VGF in HCC cells and hepatocytes in vitro, and thermal ablation induces local intrahepatic but not distant intrahepatic or systemic VGF expression in vivo.
Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications
Baldeo, Candice , Mody, Kabir , Kasi, Pashtoon Murtaza , Vishnu, Prakash , Kasi, Pashtoon Murtaza

Mayo Clinic

SAGE Open Medical Case Reports | July 4, 2018 | Volume: 6 | Issue: No issue available | Pages: No page available

10.1177/2050313x18786405 | PMID 30013790 Get It

Adverse drug reactions can be unpredictable. However, pharmacogenomic testing can help identify patients who may be more susceptible to the toxic effects of certain drugs. Genetic variations in the dihydropyrimidine dehydrogenase and thymidylate synthase genes have been shown to increase the risk of 5-fluorouracil toxicity. 5-Fluorouracil toxicity can be life threatening. Fortunately, there is treatment available for 5-fluorouracil toxicity, called uridine triacetate. Although, the indications for its use limit its administration to within 96 h of receiving 5-fluorouracil, we report a case of effective therapy in a patient started on uridine triacetate beyond the recommended 96 h, who was found to carry a thymidylate synthase gene variation but no dihydropyrimidine dehydrogenase mutations. This provides important implications for pharmacogenomic testing.